Separate names with a comma.
MindMed Published in JAMA and Phase 3 Initiative - Overview Video [MEDIA]
$MNMD Psychedelic: Exclusive talk with biopharma company MindMed MNMD...
RBC Capital Markets - MindMed: Rethinking brain health with psychedelic therapy https://www.youtube.com/watch?v=YTBUTnbte-8 Over the last 18...
(ARK) Cathy Woods bought 400k shares in ATAI on Thursday [IMG]
$ATAI TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit...
atai Life Sciences Awarded Grant from the National Institutes of Health 5-year UG3/UH3 grant will fund the optimization and early-stage...
Here are key updated facts (mid-2025) that are relevant: Phase 3 Program for MM120 ODT MindMed is running three pivotal Phase 3 trials for...
MM120 Effective as a Single Dose for Generalized Anxiety Disorder: Phase 2b Results | HCP Live Investigator Maurizio Fava, MD, chair of Mass...
H.C. Wainwright 27th Annual Global Investment Conference https://journey.ct.events/view/c1a22c93-1c8f-46ff-9ce2-c47ba55fb424
Psychedelic drug popular in 1960s could ease anxiety as doctors share warnings (Fox News)...
LSD-Based Med Safe, Effective for Anxiety in Phase 2B Trial (MedScape)...
'One and done' dose of LSD keeps anxiety at bay (NPR)...
Psychedelic Medicine Is Moving from Promise to Proof: Three Things You Should Know...
Corporate Presentation - September 2025 https://www.publicnow.com/view/D32F6090EDA4933F11C1AFB738B5ED9980DB1AA1
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the...
It will be more than that... I am thinking 6-10B
BioSpace Podcast - Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change...
The Giglamesh buyout at $1.2B is just the first domino to fall in what will likely be a wave of consolidation in the psychedelic and CNS biotech...
[IMG]
